

PLUMAS BANCORP
Form 3
October 25, 2006

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Parks Daniel L		(Month/Day/Year)	PLUMAS BANCORP [PLBC]	
(Last)	(First)	(Middle)	10/20/2006	
35 S. LINDAN AVENUE			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	
QUINCY, CA 95971			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner	6. Individual or Joint/Group Filing(Check Applicable Line)
(City)	(State)	(Zip)	<input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other	<input checked="" type="checkbox"/> Form filed by One Reporting Person
			(give title below) (specify below)	<input type="checkbox"/> Form filed by More than One Reporting Person
			Senior Vice President	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	139	I	Via 401K Plan

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of	

				Shares		(I)	
						(Instr. 5)	
Option to buy common stock	09/17/2006 ⁽¹⁾	09/17/2015	Common Stock	7,500	\$ 18.97	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Parks Daniel L 35 S. LINDAN AVENUE QUINCY, CA 95971	Â	Â	Â Senior Vice President	Â

Signatures

Daniel L. Parks 10/25/2006
 __Signature of Date
 Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
 - ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Options vest 20% per year over 5 years 1,500 exercisable at 9/17/06, 6,000 not vested and not exercisable.
 Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.
 Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. ht:bold;">

Exhibit List

Exhibit No.	Description
Exhibit 99.1	Press release dated October 30, 2013: Third Quarter 2013 Results
Exhibit 99.2	Press release dated October 29, 2013: Sanofi Launches Action 2013 , a Worldwide Employee Stock Purchase Plan
Exhibit 99.3	Press release dated October 16, 2013: Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction
Exhibit 99.4	Press release dated October 11, 2013: FDA Approves Sanofi s Nasacort® Allergy 24HR for Over-the-Counter Use
Exhibit 99.5	Genzyme Product Sales Statement, for the Product Sales Measuring Period ended September 30, 2013

Edgar Filing: PLUMAS BANCORP - Form 3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: October 30, 2013

SANOFI

By */S/ John Felitti*
Name: John Felitti
Title: Associate Vice President,
Corporate Law, Financial & Securities Law

3

Exhibit Index

Exhibit No.	Description
Exhibit 99.1	Press release dated October 30, 2013: Third Quarter 2013 Results
Exhibit 99.2	Press release dated October 29, 2013: Sanofi Launches Action 2013 , a Worldwide Employee Stock Purchase Plan
Exhibit 99.3	Press release dated October 16, 2013: Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction
Exhibit 99.4	Press release dated October 11, 2013: FDA Approves Sanofi s Nasacort® Allergy 24HR for Over-the-Counter Use
Exhibit 99.5	Genzyme Product Sales Statement, for the Product Sales Measuring Period ended September 30, 2013